C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction
Journal of Hematology & Oncology volume 15, Article number: 68 (2022)
Although chimeric antigen receptor (CAR)-modified adoptive T cell therapy is a promising immunotherapy for hematological malignancies, the efficacy improvement in relapsed/refractory acute lymphoblastic leukemia (ALL) with extramedullary infiltration and in multiple myeloma (MM) is still warranted. Since C3aR activation can promote the expansion of tumor-killing Th17 cells, we hypothesized that incorporating C3aR as a costimulatory domain would augment the antitumor activity of CAR-T. In this study, we introduced the C3aR domain into a CAR and generated BB-ζ-C3aR CAR-T targeting CD19 or BCMA. These new CAR-T exhibited a potent cytolytic ability to eradicate tumor cells expressing CD19 or BCMA in vitro. When administered intravenously to ALL or MM xenograft mouse models, BB-ζ-C3aR CAR-T reduced the tumor burden and improved the survival rate. Of note, these CAR-T could effectively eradicate subcutaneous CD19+ tumor cells, highlighting the therapeutic potential in extramedullary leukemia. Mechanistically, BB-ζ-C3aR CAR-T tended to exhibit a Th17 phenotype favoring tumor killing and suppressed Tregs. In addition, the induction of memory T cell in the BB-ζ-C3aR CAR-T cells indicated their long-term effects. Together, our findings suggest that the application of C3aR costimulation boosts the ability of CAR-T to eradicate aggressive tumor cells via Th17 expansion and memory T cell induction.
To the Editor:
The genetic engineering of T cell to express chimeric antigen receptors (CAR) is recognized as a promising approach for hematological malignancies, but the effects of CAR-T cell therapy on relapsed/refractory acute lymphoblastic leukemia (ALL) with extramedullary infiltration and on multiple myeloma (MM) are limited and need to be improved [1,2,3]. The costimulatory molecule domains in CAR are required for the activation, expansion, and survival of CAR-T. Currently, the optimal costimulatory molecules are still under investigation [4, 5]. C3aR, the receptor that recognizes the complement fragment C3a, not only mediates innate immune responses but also participates in the induction of T cell responses [6,7,8]. Thus, we introduced the C3aR domain (Additional file 1: Fig. S1a) to the 3’ end of CD3ζ, which followed the 4-1BB domain, to generate a novel type of BB-ζ-C3aR CAR.
To evaluate the efficacy of T cell bearing this new CAR in ALL or MM, an anti-CD19 scFv or anti-BCMA scFv was included in the CAR (Additional file 1: Fig. S1b-e). Initially, we detected the activity of 19-BB-ζ-C3aR CAR-T in vitro. They showed stronger cytotoxicity to tumor cells than did 19-BB-ζ controls (Fig. 1a). In vivo, NOD-SCID-IL2rg−/− (NCG) mice received an intravenous injection of NAML6-Luc cells, followed by treatment with CAR-T (2 × 106 cells intravenously administered on D2 and D8). Then, the mice were examined by serial bioluminescence imaging (BLI) (Fig. 1c). As expected, the effect of 19-BB-ζ-C3aR CAR-T was more pronounced in tumor eradication, with a better survival rate achieved than in those mice treated with the 19-BB-ζ control (Fig. 1d–f). Furthermore, lowest expression of PD-1 and fewest CD19+ blasts were found in the 19-BB-ζ-C3aR CAR-T cell group, whereas no differences were observed in the numbers of GFP+ CAR-T cell, CD4+ and CD8+ T cell among three groups (Additional file 2: Fig. S2; Fig. 1g–j).
Notably, to validate the potential of 19-BB-ζ-C3aR CAR-T in eradicating extramedullary leukemic cells, a subcutaneous leukemia mouse model was established by subcutaneously injecting 5 × 105 NALM-6 cells (Fig. 1k). Strikingly, 19-BB-ζ-C3aR CAR-T significantly suppressed the subcutaneous tumor growth (Fig. 1i–m). Although no significant differences were found in tumor volume or weight between both CAR-T cell groups (Fig. 1m, o), more mice treated with 19-BB-ζ-C3aR CAR-T cells achieved complete tumor regression (Fig. 1l) and had fewer CD19-expressing tumor cells (Fig. 1p), highlighting their potent efficacy in extramedullary leukemia.
Similarly, BB-ζ-C3aR CAR-T targeting the BCMA antigen displayed better activity and efficacy than BCMA-BB-ζ CAR-T in vitro (Additional file 3: Fig. S3a). In vivo, MM-bearing mice receiving BCMA-BB-ζ-C3aR CAR-T showed the lowest tumor burden (Fig. 2a–c) and the longest survival time (Fig. 2d) with the fewest BCMA-expressing tumor cells (Fig. 2e). Thus, BB-ζ-C3aR CAR-T cells targeting BCMA possessed potent antitumor activity against MM.
Mechanistically, we found that C3aR incorporation improved the generation of Th17 cells while suppressing the differentiation of Tregs (Fig. 1b, Additional file 4: Fig. S4a, b). Consistently, the BB-ζ-C3aR CAR-T produced high level of IL-17, IL-22, GM-CSF, and IP-10 (Additional file 5: Fig. S5). Importantly, IL-17A blockade by secukinumab could abolish the cytotoxicity of 19-BB-ζ-C3aR CAR-T cells, indicating that IL-17A/Th17 was required for the tumor eradication process (Additional file 6: Fig. S6). In vivo, both the ALL and MM models exhibited an increase in Th17 cell and a decrease in Tregs after BB-ζ-C3aR CAR-T cell administration (Additional file 4: Fig. S4c, Fig. 2f), indicating that C3aR incorporation induced CAR-T to adopt the Th17 phenotype instead of differentiating into Tregs. In addition, we assessed memory T cell subsets to evaluate the persistence of CAR-T. In both the CD4+ and CD8+ compartments, enrichment of T central memory cells (Tcm) was observed in the 19-BB-ζ-C3aR group (Additional file 4: Fig. S4d). BCMA-BB-ζ-C3aR CAR-T cell treatment also presented increases in T central memory cells (Tem) and Tcm cells (Fig. 2g), suggesting that C3aR incorporation promoted the memory function of CAR-T.
In summary, we reported that C3aR, a novel costimulatory domain, significantly enhanced the antitumor ability of CAR-T and specifically improved therapeutic efficacy in extramedullary leukemia. BB-ζ-C3aR CAR-T promoted tumor eradication with long-term effects through Th17 expansion and memory T cell induction. These results not only highlight the importance of optimizing CAR engineering but also provide evidence that BB-ζ-C3aR CAR-T cells may be effective in treating refractory tumors, such as extramedullary leukemia and solid tumors.
Availability of data and materials
All data generated or analyzed during this study are included in this published article or its supplementary information files. The raw datasets are available from the corresponding authors on reasonable request.
Acute lymphoblastic leukemia
Chimeric antigen receptor
Chimeric antigen receptor T cell
T central memory cells
T effector memory cells
Regulatory T cells
Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13(1):86.
Liang Y, Liu H, Lu Z, Lei W, Zhang C, Li P, et al. CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies. J Hematol Oncol. 2021;14(1):26.
Castelletti L, Yeo D, van Zandwijk N, Rasko JEJ. Anti-Mesothelin CAR T cell therapy for malignant mesothelioma. Biomark Res. 2021;9(1):11.
Weng J, Lai P, Qin L, Lai Y, Jiang Z, Luo C, et al. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia. J Hematol Oncol. 2018;11(1):25.
Guedan S, Posey AD Jr, Shaw C, Wing A, Da T, Patel PR, et al. Enhancing CAR T cell persistence through ICOS and 4–1BB costimulation. JCI Insight. 2018;3(1):e96976.
Liu Y, Wang K, Liang X, Li Y, Zhang Y, Zhang C, et al. Complement C3 produced by macrophages promotes renal fibrosis via IL-17A secretion. Front Immunol. 2018;9:2385.
Gadwa J, Bickett TE, Darragh LB, Knitz MW, Bhatia S, Piper M, et al. Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer. J Immunother Cancer. 2021;9(3):e002585.
Liu J, Lin F, Strainic MG, An F, Miller RH, Altuntas CZ, et al. IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production. J Immunol. 2008;180(9):5882–9.
This work was supported by the National Key R&D Program of China (No. 2017YFE0131600); National Natural Science Foundation of China (Nos. 81870121, 82100228); Guangdong Basic and Applied Basic Research Foundation (Nos. 2019A1515010094, 2019A1515012049); NSFC Incubation Project of Guangdong Provincial People's Hospital (KY0120220024); and High-level Hospital Construction Project of Guangdong Provincial People's Hospital (DFJHBF202107).
Ethics approval and consent to participate
All the animal procedures were performed in accordance with the rules of the IACUC in the Guangdong Provincial People's Hospital.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Generation of the BB-ζ-C3aR CAR-T cells targeting CD19 or BCMA. a The amino acid sequence of incorporated C3aR domain. b Schematic representation of chimeric antigen receptors that contain C3aR as a costimulation signal associated with 4-1BB in the intracellular domains, CD19-scFv, and the CD3ζ signal transduction domain. c Transduction efficiency of T cell was determined by flow cytometry. Representative results are from at least three independent experiments. d Schematic representation of chimeric antigen receptors that contain the C3aR as a costimulation signal associated with 4-1BB in the intracellular domain, BCMA-scFv, and the CD3ζ signal transduction domain. e Transduction efficiency of T cell was determined by flow cytometry.
The expression of PD-1 was reduced in the 19-BB-ζ-C3aR CAR-T cells. The expression of PD-1 on T cell was determined by flow cytometry. The results showed that BB-ζ-C3aR CAR-T cells presented lower expression of PD-1 compared with mock T or BB-ζ CAR-T cells. *p ≤ 0.05.
BCMA-BB-ζ-C3aR CAR-T cells exhibited potent anti-tumor activity in vitro. a The results of cytotoxicity assay showed that BCMA-BB-ζ-C3aR CAR-T cells have improved the ability to lyse BCMA+ MM cells compared to BCMA-BB-ζ CAR-T cells. b Flow cytometry and the statistics revealed that BCMA-BB-ζ-C3aR CAR-T cells treatment group showed more IL-17-expressing Th17 cells and less CD4+CD25+FoxP3+ Tregs compared to BCMA-BB-ζ and mock-transduced T cells group. ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05.
C3aR incorporation induced CAR-T cells to display phenotypes of Th17 and memory T cells in vivo. The statistics of IL-17-expressing Th17 cells (a) and CD4+CD25+FoxP3+ Tregs (b) in the co-culture system of CAR-T and CD19 expressing tumors. c In the xenograft leukemic mice, the 19-BB-ζ-C3aR CAR-T cells exhibited elevated expansion of Th17 cell phenotype. d In the 19-BB-ζ-C3aR CAR-T group, Tcm cells were highly induced in CD4+ and CD8+ T cells compared to those from 19-BB-ζ CAR-T group. No difference was observed in the percentage of Tem cells between both groups. ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05.
19-BB-ζ-C3aR CAR-T presented with an expression elevation of some cytokines. In vitro, increased expressions of IL-17, IL-22, GS-CSF, and IP-10 were observed in the 19-BB-ζ-C3aR CAR-T, whereas no differences in TNF-a and IFN-r were found between 19-BB-ζ-C3aR CAR-T and 19-BB-ζ CAR-T. **p ≤ 0.01, *p ≤ 0.05, n.s. no significant.
IL-17A blockade by secukinumab impaired the tumor eradication effect of 19-BB-ζ-C3aR CAR-T. In vitro, secukinumab, a human IgG1κ monoclonal antibody that binds to the IL-17A, suppressed the cytotoxicity of 19-BB-ζ-C3aR CAR-T on CD19-expressing NALM6 cells. ***p ≤ 0.001, **p ≤ 0.01.
Materials and Methods.
About this article
Cite this article
Lai, P., Chen, X., Wang, Y. et al. C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction. J Hematol Oncol 15, 68 (2022). https://doi.org/10.1186/s13045-022-01288-2
- Chimeric antigen receptor-modified T cell
- Extramedullary leukemia
- Multiple myeloma